Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta (clinicaltrials.gov) - Sep 11, 2026 - P2 | N=15 | Completed | Sponsor: Sionna Therapeutics Inc. | Active, not recruiting ➔ Completed
Trial completion • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases
|